Katsuyuki Hotta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2448024/publications.pdf

Version: 2024-02-01

		126907	13771
188	18,092	33	129
papers	citations	h-index	g-index

192	192	192	16103
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan. Internal Medicine, 2022, 61, 379-383.	0.7	1
2	Identification of targetable kinases in idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, 20.	3.6	8
3	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. International Journal of Clinical Oncology, 2022, 27, 695-706.	2.2	11
4	First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1869-1877.	2.5	5
5	Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801. International Journal of Clinical Oncology, 2022, 27, 1139-1144.	2.2	7
6	Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report. Case Reports in Oncology, 2022, 15, 494-498.	0.7	1
7	Three doses of mRNA COVIDâ€19 vaccine protects from SARSâ€CoVâ€2 infections in Japan. Journal of Internal Medicine, 2022, 292, 687-689.	6.0	2
8	Preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: An open-label, randomized, phase II study.. Journal of Clinical Oncology, 2022, 40, TPS12141-TPS12141.	1.6	0
9	CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer. Cancer Immunology Research, 2022, 10, 1111-1126.	3.4	10
10	Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 101-106.	4.2	26
11	Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer. Japanese Journal of Clinical Oncology, 2021, 51, 279-286.	1.3	7
12	Durvalumab, with or without tremelimumab, plus platinumâ€“etoposide versus platinumâ€“etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 51-65.	10.7	356
13	Randomized study comparing mannitol with furosemide for the prevention of cisplatinâ€induced renal toxicity in nonâ€small cell lung cancer: The OLCSG1406 trial. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 101-108.	1.1	7
14	Novel prospective umbrellaâ€type lung cancer registry study for clarifying clinical practice patterns: <scp>CSâ€Lung</scp>â€003 study protocol. Thoracic Cancer, 2021, 12, 725-731.	1.9	2
15	Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. JTO Clinical and Research Reports, 2021, 2, 100107.	1.1	15
16	An Evaluation of the Safety and Feasibility of Adenosine-assisted Clipping Surgery for Unruptured Cerebral Aneurysms: Study Protocol. Neurologia Medico-Chirurgica, 2021, 61, 393-396.	2.2	4
17	A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401. Supportive Care in Cancer, 2021, 29, 5237-5244.	2.2	0
18	Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. Respiratory Investigation, 2021, 59, 240-246.	1.8	3

#	Article	IF	Citations
19	Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3749-3755.	2.5	6
20	VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogeneâ€driven nonâ€smallâ€cell lung cancers. Cancer Science, 2021, 112, 1853-1864.	3.9	29
21	Classification and Treatment of Oligometastatic Disease in Non-Small-Cell Lung Cancer. Japanese Journal of Lung Cancer, 2021, 61, 95-99.	0.1	0
22	First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. International Journal of Clinical Oncology, 2021, 26, 1073-1082.	2.2	9
23	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. Japanese Journal of Clinical Oncology, 2021, 51, 956-965.	1.3	6
24	Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301. BMC Cancer, 2021, 21, 506.	2.6	3
25	Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.. Journal of Clinical Oncology, 2021, 39, e20590-e20590.	1.6	0
26	The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with nonâ€“small-cell lung cancer differ based on PD-L1 expression. European Journal of Cancer, 2021, 149, 73-81.	2.8	34
27	A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6â€“RET fusion gene and NF1/TP53 mutations. Lung Cancer, 2021, 156, 1-4.	2.0	7
28	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naÃ¯ve ALK-, ROS1-, or EGFR-altered Nonâ€“small Cell Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 1653-1662.	4.1	7
29	Survival of chemo-naÃ¯ve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. Japanese Journal of Clinical Oncology, 2021, 51, 1269-1276.	1.3	7
30	Triple therapy with osimertinib, bevacizumab and cetuximab in EGFRâ€'mutant lung cancer with HIFâ€'1Î±/TGFâ€Îº expression. Oncology Letters, 2021, 22, 639.	1.8	1
31	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Nonâ€“Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score â‰¥ 50%. Journal of Clinical Oncology, 2021, 39, 2339-2349.	1.6	468
32	Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression. European Journal of Cancer, 2021, 157, 523-524.	2.8	0
33	Firstâ€line pembrolizumab vs chemotherapy in metastatic nonâ€smallâ€cell lung cancer: KEYNOTEâ€024 Japan subset*. Cancer Science, 2021, 112, 5000-5010.	3.9	6
34	Protocol for a multi-site, clusterâ€randomized, phase III, comparative clinical trial of geriatric assessment of older patients with nonâ€smallâ€cell lung cancer: the ENSURE-GA study. BMC Geriatrics, 2021, 21, 74.	2.7	5
35	Crizotinib for recurring nonâ€smallâ€cell lung cancer with EML4â€ALK fusion genes previously treated with alectinib: A phase II trial. Thoracic Cancer, 2021, 12, 643-649.	1.9	5
36	A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer, 2021, 162, 140-146.	2.0	32

#	Article	IF	Citations
37	JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma. , 2021, 9, e003288.		9
38	Patientsâ€™ preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. Acta OncolÃ³gica, 2020, 59, 324-328.	1.8	2
39	Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review. Internal Medicine, 2020, 59, 823-828.	0.7	9
40	The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer, 2020, 139, 140-145.	2.0	68
41	Nivolumab for the treatment of unresectable pleural mesothelioma. Expert Opinion on Biological Therapy, 2020, 20, 109-114.	3.1	11
42	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. Acta OncolÃ³gica, 2020, 59, 249-256.	1.8	28
43	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2020, 139, 195-199.	2.0	100
44	Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. Biochemical and Biophysical Research Communications, 2020, 532, 341-346.	2.1	10
45	Utility of immune checkpoint inhibitors in nonâ€smallâ€cell lung cancer patients with poor performance status. Cancer Science, 2020, 111, 3739-3746.	3.9	20
46	Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. Lung Cancer, 2020, 150, 83-89.	2.0	9
47	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. Japanese Journal of Clinical Oncology, 2020, 50, 1447-1453.	1.3	14
48	Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer, 2020, 149, 46-52.	2.0	28
49	Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma. , 2020, 8, e000461.		26
50	Pilot evaluation of a HER2 testing in non-small-cell lung cancer. Journal of Clinical Pathology, 2020, 73, 353-357.	2.0	12
51	Durvalumab Â± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.. Journal of Clinical Oncology, 2020, 38, 9002-9002.	1.6	36
52	First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.. Journal of Clinical Oncology, 2020, 38, 9068-9068.	1.6	10
53	Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction. Oncology Letters, 2020, 20, 1-1.	1.8	4
54	Revision of Lung Cancer Clinical Practice Guidelines -Focusing on the Area of Pharmacotherapy-. Japanese Journal of Lung Cancer, 2020, 60, 910-912.	0.1	0

#	Article	IF	Citations
55	A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an <i>EGFR</i> Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages. Internal Medicine, 2019, 58, 3033-3037.	0.7	7
56	Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracilâ€“tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial. International Journal of Clinical Oncology, 2019, 24, 1367-1376.	2.2	4
57	Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. Journal of Thoracic Oncology, 2019, 14, 2009-2018.	1.1	22
58	EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice. Lung Cancer, 2019, 136, 86-93.	2.0	7
59	Durvalumab plus platinumâ€“etoposide versus platinumâ€“etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, The, 2019, 394, 1929-1939.	13.7	1,274
60	Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab. Internal Medicine, 2019, 58, 985-989.	0.7	25
61	Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutation with a History of Acquired Resistance to Osimertinib. Internal Medicine, 2019, 58, 1625-1627.	0.7	3
62	Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. Respiratory Investigation, 2019, 57, 460-465.	1.8	2
63	Physician requests by patients with malignant pleural mesothelioma in Japan. BMC Cancer, 2019, 19, 383.	2.6	7
64	A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY). Chest, 2019, 156, 357-366.	0.8	25
65	The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2019, 49, 762-765.	1.3	43
66	Recent trends in the treatment of unresectable stage III non-small-cell lung cancer. Respiratory Investigation, 2019, 57, 330-336.	1.8	5
67	Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. International Journal of Clinical Oncology, 2019, 24, 461-467.	2.2	7
68	Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. Japanese Journal of Clinical Oncology, 2019, 49, 458-464.	1.3	17
69	A phase I/II trial of weekly nabâ€paclitaxel for pretreated nonâ€smallâ€cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 250-256.	1.1	3
70	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2019, 393, 1819-1830.	13.7	2,347
71	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Nonâ€“Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 2019, 37, 537-546.	1.6	1,144
72	Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. Lung Cancer, 2019, 132, 54-58.	2.0	15

#	Article	IF	Citations
73	Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. International Journal of Clinical Oncology, 2019, 24, 41-45.	2.2	5
74	Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Nonâ€“Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. Clinical Lung Cancer, 2019, 20, 134-138.	2.6	19
75	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan. Lung Cancer, 2019, 129, 55-62.	2.0	29
76	Revision of Lung Cancer Clinical Practice Guidelines -Focusing on the Area of Pharmacotherapy-. Japanese Journal of Lung Cancer, 2019, 59, 1076-1078.	0.1	0
77	Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. Japanese Journal of Clinical Oncology, 2018, 48, 287-290.	1.3	3
78	MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. Scientific Reports, 2018, 8, 1955.	3.3	34
79	A Phase II Study of Trastuzumab Emtansine in HER2-Positive Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 273-279.	1.1	119
80	Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study. BMC Cancer, 2018, 18, 350.	2.6	8
81	A Multicenter Randomized Controlled Study ofÂPaclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy inÂResected Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 699-706.	1.1	24
82	A phase I trial of afatinib and bevacizumab in chemo-naÃ¯ve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. Lung Cancer, 2018, 115, 103-108.	2.0	25
83	Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. Biochemical and Biophysical Research Communications, 2018, 495, 360-367.	2.1	15
84	Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion?. Annals of Thoracic and Cardiovascular Surgery, 2018, 24, 131-138.	0.8	2
85	Exploration of resistance mechanisms for epidermal growth factor receptorâ€tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and nextâ€generation sequencing. Cancer Science, 2018, 109, 3921-3933.	3.9	27
86	Combined effect of cabozantinib and gefitinib in crizotinibâ€resistant lung tumors harboring <scp>ROS</scp>1 fusions. Cancer Science, 2018, 109, 3149-3158.	3.9	20
87	Pembrolizumab for the first-line treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy, 2018, 18, 1015-1021.	3.1	18
88	A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol. Clinical Lung Cancer, 2018, 19, e705-e707.	2.6	23
89	Phase II study of ceritinib in alectinibâ€pretreated patients with anaplastic lymphoma kinaseâ€rearranged metastatic nonâ€smallâ€cell lung cancer in Japan: <scp>ASCEND</scp>â€9. Cancer Science, 2018, 109, 2863-2872.	3.9	42
90	Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors. Clinical Lung Cancer, 2018, 19, e861-e864.	2.6	27

#	Article	IF	Citations
91	Gemcitabine-cisplatin (GC) + necitumumab (N) versus GC as first-line treatment for stage IV squamous cell lung cancer (SqCLC): An open-label randomized multicenter phase Ib-II trial in Japan.. Journal of Clinical Oncology, 2018, 36, 9038-9038.	1.6	2
92	Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. Oncotarget, 2018, 9, 29525-29531.	1.8	28
93	Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet, The, 2017, 390, 29-39.	13.7	753
94	Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. Japanese Journal of Clinical Oncology, 2017, 47, 434-437.	1.3	6
95	Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin. Annals of Thoracic Surgery, 2017, 104, 971-978.	1.3	5
96	Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790MinÂvivo. Molecular Oncology, 2017, 11, 670-681.	4.6	14
97	PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS â‰¥50%:ÂData from KEYNOTE-024. Journal of Thoracic Oncology, 2017, 12, S8-S9.	1.1	11
98	Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Nonâ€“Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol. Clinical Lung Cancer, 2017, 18, 245-249.	2.6	8
99	A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. Lung Cancer, 2017, 112, 188-194.	2.0	5
100	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncology, The, 2017, 18, 1600-1609.	10.7	282
101	Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. Clinical Lung Cancer, 2017, 18, 241-244.	2.6	9
102	Trastuzumab Emtansine in HER2+ Recurrent Metastatic Nonâ€“Small-Cell Lung Cancer: Study Protocol. Clinical Lung Cancer, 2017, 18, 92-95.	2.6	19
103	Treatment Rationale and Design for J-AXEL: AÂRandomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 100-103.	2.6	9
104	Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 3076-3086.	1.4	4
105	Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) â‰¥50% enrolled in KEYNOTE-024.. Journal of Clinical Oncology, 2017, 35, 9000-9000.	1.6	43
106	Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naÃ¯ve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC).. Journal of Clinical Oncology, 2017, 35, 9064-9064.	1.6	14
107	Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting. Anticancer Research, 2017, 37, 1507-1514.	1.1	7
108	Clinical features of squamous cell lung cancer with targetable gene alterations in a nationwide genomic screening network in Japan (LC-SCRUM-Japan).. Journal of Clinical Oncology, 2017, 35, 9057-9057.	1.6	0

#	Article	IF	Citations
109	Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation. OncoTargets and Therapy, 2016, 9, 1753.	2.0	4
110	Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study. Japanese Journal of Clinical Oncology, 2016, 46, 871-874.	1.3	17
111	Pharmacologic study (<scp>JP</scp>28927) of alectinib in Japanese patients with ALK+ nonâ€smallâ€cell lung cancer with or without prior crizotinib therapy. Cancer Science, 2016, 107, 1642-1646.	3.9	15
112	Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA nonâ€“small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701. Japanese Journal of Clinical Oncology, 2016, 46, 741-747.	1.3	8
113	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Cancer Chemotherapy and Pharmacology, 2016, 78, 941-947.	2.3	6
114	Pembrolizumab versus Chemotherapy for PD-L1â€“Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2016, 375, 1823-1833.	27.0	7,847
115	A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102. Cancer Chemotherapy and Pharmacology, 2016, 78, 769-774.	2.3	7
116	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Nonâ€“Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). Clinical Lung Cancer, 2016, 17, 602-605.	2.6	10
117	The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy. Annals of Thoracic Surgery, 2016, 102, 985-992.	1.3	7
118	Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. Cancer Chemotherapy and Pharmacology, 2016, 77, 1005-1009.	2.3	14
119	Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography. Japanese Journal of Clinical Oncology, 2016, 46, 529-533.	1.3	2
120	Nonâ€“Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Cancer Research, 2016, 76, 1506-1516.	0.9	115
121	Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Nonâ€“Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol. Clinical Lung Cancer, 2016, 17, 75-79.	2.6	13
122	Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. International Journal of Clinical Oncology, 2016, 21, 81-87.	2.2	26
123	Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study.. Journal of Clinical Oncology, 2016, 34, 9008-9008.	1.6	58
124	Second primary cancer in survivors of locally advanced NSCLC treated with concurrent chemoradiation followed by surgery.. Journal of Clinical Oncology, 2016, 34, 10100-10100.	1.6	0
125	Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. Japanese Journal of Clinical Oncology, 2015, 45, 603-4.	1.3	12
126	Downregulation of TBXAS 1 in an ironâ€induced malignant mesothelioma model. Cancer Science, 2015, 106, 1296-1302.	3.9	14

#	Article	IF	Citations
127	Lower lobe origin is a poor prognostic factor in locally advanced non-small-cell lung cancer patients treated with induction chemoradiotherapy. Molecular and Clinical Oncology, 2015, 3, 706-712.	1.0	18
128	Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review. PLoS ONE, 2015, 10, e0121211.	2.5	16
129	Endobronchial ultrasound-guided transbronchial biopsy with or without a guide sheath for diagnosis of lung Cancer. Respiratory Investigation, 2015, 53, 93-97.	1.8	18
130	A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0501. Lung Cancer, 2015, 87, 141-147.	2.0	30
131	Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. Cancer Chemotherapy and Pharmacology, 2015, 76, 251-256.	2.3	11
132	Phase II study of topotecan and cisplatin with sequential radiotherapy in elderly small cell lung cancer patients (Okayama Lung Cancer Study Group; OLCSG 0102).. Journal of Clinical Oncology, 2015, 33, 7572-7572.	1.6	1
133	Development of skin rash within the 1st week is a potential surrogate marker of therapeutic effect in afatinib monotherapy in patients with EGFR-mt non-small-cell lung cancer (NSCLC): Okayama Lung Cancer Study Group Experience.. Journal of Clinical Oncology, 2015, 33, e19051-e19051.	1.6	1
134	Publication of Lung Cancer Clinical Trials in Japan. Japanese Journal of Lung Cancer, 2015, 55, 1070-1074.	0.1	0
135	A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy. Okayama Igakkai Zasshi, 2015, 127, 127-133.	0.0	1
136	Three-arm randomized trial of sodium alginate, orally administered mucoprotective agent, for preventing radiation esophagitis in pts with locally advanced non-small-cell lung cancer (LA-NSCLC) receiving concurrent chemoradiotherapy (CRT): Okayama Lung Cancer Study Group 1401.. Journal of Clinical Oncology, 2015, 33, TPS9641-TPS9641.	1.6	0
137	Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation. Drug Design, Development and Therapy, 2014, 8, 2401.	4.3	3
138	Rapid on-site evaluation with BIOEVALUATORÂ®during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing pulmonary and mediastinal diseases. Annals of Thoracic Medicine, 2014, 9, 14.	1.8	12
139	Current status and future perspectives of cooperative study groups for lung cancer in Japan. Respiratory Investigation, 2014, 52, 339-347.	1.8	3
140	A New Human Lung Adenocarcinoma Cell Line Harboring the EML4-ALK Fusion Gene. Japanese Journal of Clinical Oncology, 2014, 44, 963-968.	1.3	11
141	A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0801. European Journal of Cancer, 2014, 50, 2783-2790.	2.8	18
142	Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemotherapy and Pharmacology, 2014, 73, 943-950.	2.3	8
143	A Survey of Japanese Thoracic Oncologists' Perception of Diagnostic and Treatment Strategies for EGFR Mutant or EML4-ALK Fusion Non-small Cell Lung Cancer. Chest, 2014, 146, e222-e225.	0.8	4
144	Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study.. Journal of Clinical Oncology, 2014, 32, 8103-8103.	1.6	6

#	Article	IF	Citations
145	Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC.. Journal of Clinical Oncology, 2014, 32, e19102-e19102.	1.6	0
146	Time trend in the survival advantage in phase III trials investigating molecular-targeted agents for advanced non-small cell lung cancer (NSCLC) during the past decade.. Journal of Clinical Oncology, 2014, 32, e19084-e19084.	1.6	0
147	A phase II study of S-1 and concurrent thoracic radiotherapy (TRT) for elderly pts with locally advanced non-small cell lung cancer (LA-NSCLC): Okayama Lung Cancer Study Group trial 0801.. Journal of Clinical Oncology, 2014, 32, 7576-7576.	1.6	0
148	Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer, 2013, 81, 435-439.	2.0	28
149	Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer, 2013, 79, 20-26.	2.0	39
150	Reappraisal of Short-term Low-volume Hydration in Cisplatin-based Chemotherapy: Results of a Prospective Feasibility Study in Advanced Lung Cancer in the Okayama Lung Cancer Study Group Trial 1002. Japanese Journal of Clinical Oncology, 2013, 43, 1115-1123.	1.3	48
151	Impact of concomitant use of anti-acid agents on efficacy of gefitinib in EGFR-mutant non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19008-e19008.	1.6	1
152	Impact of body surface area (BSA) on efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19167-e19167.	1.6	0
153	Survival analysis of induction cisplatin (CDDP)-docetaxel (DOC)-bevacizumab (BEV) chemotherapy followed by maintenance BEV-pemetrexed (PEM) therapy in advanced nonsquamous non-small cell lung cancer (NonSq NSCLC): A phase II trial from Okayama Lung Cancer Study Group 0903.. Journal of Clinical Oncology, 2013, 31, e19040-e19040.	1.6	0
154	Prospective cohort study of serum sialylated glycoprotein (KL-6) as a prognostic marker in patients (pts) with non-small cell lung cancer (NSCLC) receiving gefitinib monotherapy: Okayama Lung Cancer Study Group 0703.. Journal of Clinical Oncology, 2013, 31, e19023-e19023.	1.6	0
155	A survey on Japanese thoracic oncologistsâ€™ preference on treatment strategy for EGFR-mutant or EML4-ALK-mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19124-e19124.	1.6	0
156	Impact of body surface area on efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutation.. Journal of Clinical Oncology, 2012, 30, 2607-2607.	1.6	1
157	A phase II trial of induction gefitinib monotherapy followed by cisplatin-docetaxel and concurrent thoracic irradiation in patients with EGFR-mutant locally advanced non-small-cell lung cancer (LA-NSCLC): LOGIK0902/OLCSG0905 intergroup trial.. Journal of Clinical Oncology, 2012, 30, 7045-7045.	1.6	2
158	Survival post-progression (SPP) in phase III trials of chemotherapy in advanced NSCLC: Its potentially different impact on OS in the first-line and salvage settings.. Journal of Clinical Oncology, 2012, 30, e18027-e18027.	1.6	0
159	Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: Okayama Lung Cancer Study Group experience.. Journal of Clinical Oncology, 2012, 30, 7576-7576.	1.6	0
160	Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review. PLoS ONE, 2011, 6, e26646.	2.5	66
161	Cure- or Care-Oriented Regimen for Stage III Nonâ€“Small-Cell Lung Cancer?. Journal of Clinical Oncology, 2011, 29, e320-e320.	1.6	6
162	Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2011, 11, 993-999.	2.4	5

#	Article	IF	Citations
163	Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience. Journal of Thoracic Oncology, 2010, 5, 179-184.	1.1	69
164	A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705. Journal of Thoracic Oncology, 2010, 5, 99-104.	1.1	67
165	Desire for Information and Involvement in Treatment Decisions: Lung Cancer Patients' Preferences and Their Physicians' Perceptions: Results from Okayama Lung Cancer Study Group Trial 0705. Journal of Thoracic Oncology, 2010, 5, 1668-1672.	1.1	18
166	Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Nonâ€“Small-Cell Lung Cancer: OLCSG 0007. Journal of Clinical Oncology, 2010, 28, 3299-3306.	1.6	225
167	Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Lung Cancer, 2010, 70, 308-312.	2.0	8
168	A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization. Acta OncolÃ³gica, 2009, 48, 471-473.	1.8	1
169	Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. Journal of Cancer Research and Clinical Oncology, 2009, 135, 117-123.	2.5	7
170	Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 311-317.	1.1	55
171	Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer. Lung Cancer, 2008, 62, 236-241.	2.0	9
172	Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 477-482.	1.1	49
173	Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in 143 Phase III Trials. Journal of Thoracic Oncology, 2007, 2, 402-407.	1.1	67
174	Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 632-637.	1.1	62
175	Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy. Lung Cancer, 2007, 55, 343-348.	2.0	5
176	Long-Standing Debate on Cisplatin- Versus Carboplatin-Based Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 96.	1.1	35
177	Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer, 2007, 109, 939-948.	4.1	44
178	Author reply to recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of firstâ€line, systemic chemotherapy. Cancer, 2007, 110, 2594-2594.	4.1	1
179	Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation. Oncology Reports, 2007, 17, 313-7.	2.6	23
180	Role of early serial change in serum carcinoembryonic antigen levels as a predictive marker for radiological response to gefitinib in Japanese patients with non-small cell lung cancer. Anticancer Research, 2007, 27, 1737-41.	1.1	3

#	Article	IF	Citations
181	Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer. Current Opinion in Oncology, 2006, 18, 144-150.	2.4	8
182	A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 57, 755-760.	2.3	5
183	Interstitial Lung Disease in Japanese Patients With Non-Small Cell Lung Cancer Receiving Gefitinib. Cancer Journal (Sudbury, Mass), 2005, 11, 417-424.	2.0	68
184	Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group Experience. Acta OncolÃ³gica, 2005, 44, 717-722.	1.8	19
185	Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: Results from a prospective feasibility study. Lung Cancer, 2005, 50, 413-415.	2.0	9
186	Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2004, 22, 3852-3859.	1.6	373
187	Effect of gefitinib (â€˜Iressaâ€™, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer, 2004, 46, 255-261.	2.0	175
188	An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Lung Cancer, 2004, 46, 61-76.	2.0	30